Investigating Tradipitant for Motion Sickness Relief
Motion Delos: An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel
This study is testing if a new medication called tradipitant can help adults aged 18 to 75 feel better during travel when they experience motion sickness.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Vanda Pharmaceuticals Industry-sponsored |
| Locations | 1 site (Santa Monica, California) |
| Trial ID | NCT06138613 on ClinicalTrials.gov |
What this trial studies
This open label study aims to evaluate the safety and efficacy of tradipitant in individuals experiencing motion sickness during travel. Participants, aged 18 to 75, will be monitored for their response to the treatment in situations known to induce motion sickness. The study focuses on assessing how well tradipitant alleviates symptoms associated with motion sickness. By using an open label design, all participants will know they are receiving the treatment, which allows for real-world assessment of its effects.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 with a history of motion sickness.
Not a fit: Patients with nausea-inducing disorders other than motion sickness or those with a BMI over 40 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide an effective treatment option for individuals suffering from motion sickness.
How similar studies have performed: Other studies have explored treatments for motion sickness, but the specific use of tradipitant in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of Motion Sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI \> 40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Where this trial is running
Santa Monica, California
- Santa Monica Clinical Trials — Santa Monica, California, United States (Recruiting)
Study contacts
- Study coordinator: Vanda Pharmaceuticals
- Email: clinicaltrials@vandapharma.com
- Phone: 2027343400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.